Observational studyBMC ophthalmology2026
Micro Aberration Scatter Index (MASI) as an objective proxy for contrast sensitivity after keratorefractive surgery: a prospective observational study.
Observational study in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the Micro Aberration Scatter Index (MASI) as an objective proxy for visual quality after keratorefractive surgery.
methodsThis prospective study included 200 eyes from 200 patients who underwent uneventful KLEx, PRK, or LASIK. Monocular testing was performed 30 days postoperatively. MASI was derived from pyramidal wavefront aberrometry (OSIRIS-T, CSO). Contrast sensitivity was measured at 3, 6, 12, and 18 cycles per degree (cpd) under photopic conditions using sine-wave grating charts. Uncorrected distance visual acuity (UDVA) was recorded in logMAR. Correlation, regression, and tertile subgroup analyses were performed.
resultsMASI values ranged from 13.1 to 79.5 (mean 34.0 ± 13.3). MASI showed significant inverse correlations with contrast sensitivity at all spatial frequencies (r = - 0.46 to - 0.62; all p < 0.001). Strongest relationship was at 18 cpd (r = - 0.62, R²=0.39). Linear regression showed each 10-point increase in MASI predicted a 0.18 unit decrease in contrast sensitivity at 18 cpd. MASI tertiles corresponded with differences in contrast sensitivity and uncorrected acuity. Stratification by MASI tertile revealed significant differences in visual performance: low MASI (mean 21 ± 4) had 18 cpd contrast sensitivity of1.30 ± 0.24 and mean UDVA of - 0.12 ± 0.09 logMAR; mid MASI (mean 31 ± 4) had 18 cpd contrast sensitivity of1.21 ± 0.31 and mean UDVA of - 0.13 ± 0.07 logMAR; high MASI (49 ± 9) had 18 cpd contrast sensitivity of0.86 ± 0.40 and UDVA of - 0.05 ± 0.14 logMAR (both p < 0.001).
conclusionsMASI shows early promise as a fast and clinically feasible index of optical quality. Within a single device and operator it correlated strongly with functional vision and distinguished subtle visual degradation not captured by high-contrast acuity alone. Because MASI is computed over the central 3 mm zone, its application to mesopic and night-vision symptoms should be regarded as hypothesis-generating, and inter-device, inter-operator, and multicenter reproducibility remain to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.